Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for Stroke

Launched by THE FOUNDATION FOR ORTHOPAEDICS AND REGENERATIVE MEDICINE · Dec 2, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a new treatment for stroke using special cells called mesenchymal stem cells, which are taken from umbilical cords. In this study, these cells will be given to participants through an intravenous infusion, meaning they will receive the treatment through a vein. The goal is to see if this approach can help improve outcomes for people who have had a stroke.

To join the trial, participants must have been diagnosed with a stroke and be willing to sign a consent form that explains the study. However, there are some important reasons why someone might not be able to participate, such as having an active infection, cancer, or certain medical conditions that could affect their safety. This trial is currently recruiting participants of all genders and ages, and those who qualify can expect close monitoring throughout the study to ensure their safety and wellbeing.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Stroke
• • Understanding and willingness to sign a written informed consent document
• Exclusion Criteria:
• • Active infection
• • Active cancer
• • Chronic multisystem organ failure
• • Pregnancy
• • Clinically significant Abnormalities on pre-treatment laboratory evaluation
• • Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
• • Continued drug abuse
• • Pre-menopausal women not using contraception
• • Previous organ transplant
• • Hypersensitivity to sulfur